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 Metabolic syndrome (MS) is characterized 
by hypertension, abdominal obesity, increased 
triglycerides and blood glucose and decreased HDL 
cholesterol1,2 and is associated with an increased risk 
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Background & objectives:  The  metabolic  syndrome  (MS)  is  a  risk  factor  for  development   of   
cardiovascular disease  and is closely associated   with obstructive sleep apnoea (OSA). Co-occurrence of 
both OSA and MS is called syndrome Z. It has been hypothesized that the OSA may be a manifestation of 
MS.  We collected data on polysomnography (PSG)  and biochemical investigations on middle aged urban 
Indians during a community based study in South Delhi while studying prevalence of obstructive sleep 
apnoea  and analysed to find out  the ages at which the OSA, MS and syndrome Z exist in these subjects.
Methods: A 2-stage, cross-sectional, population-based study in subjects of either gender between 30-65 
yr of age in 4 different socio-economic zones of the South Delhi, India, was performed earlier (from 
April 2005 through June 2007). In-hospital, supervised   PSG studies were performed  and biochemical 
investigations for the MS  using National Cholesterol Education Programmme Adult Treatment Panel 
(NCEP ATP) III criteria were carried out. In this communication, the data were further analysed to 
estimate the  prevalences of   MS alone, OSA alone and syndrome Z and average ages of 3 conditions.
Results:  Three hundred and fifty one subjects had satisfactory PSG  studies.  The MS  alone was  present 
in 105  [29.9%; (95% CI 25.1-34.7)] while  OSA  alone  was  present  in 24 [6.8%; (95% CI 4.2-9.5)]  
subjects  and   the syndrome Z was present in 70 [19.9%; (95% CI 15.8-24.1)]  subjects.  Median ages 
of normal subjects, and subjects with MS, OSA and syndrome Z were 40, 43, 43 and 47 yr respectively. 
Minimum ages of normal subjects, and subjects with MS, OSA and syndrome Z were 30, 30, 32 and 32 
yr respectively. 
Interpretation & conclusions:  When  body mass index (BMI) was normal, the increasing median ages 
of these conditions indicated that the MS  may be the  first event followed  by  OSA  and  eventually  
syndrome  Z  develops.  With BMI >25 or >30 no clear-cut difference was noted, indicating that the BMI 
itself could have an independent role in MS, OSA and syndrome Z.
Key words Metabolic syndrome -  obstructive sleep apnoea -  prevalence -  South Asians -  Indians -  syndrome Z
for the development of type 2 diabetes mellitus3 and 
cardiovascular disease4. Several studies suggest that 
the prevalence of MS according to National Cholesterol 
Education Programme Adult Treatment Panel 
(NCEP-ATP) III criteria is about 40 per cent greater 
in obstructive sleep apnoea (OSA)5. Though there 
is circumstantial evidence to implicate OSA in the 
development of MS, the causal relationship, remains 
unproven. Animal studies suggest that diabetes may 
lead to a marked depression in ventilatory control 
mechanisms6. It has been hypothesized that in the setting 
of OSA and MS, there probably exists feedforward 
relationship between the two which leads to further 
aggravation of both disorders. It has been proposed that 
the OSA may be one of the manifestations of MS7,8. 
Though several human studies suggest that the OSA 
is independently associated with insulin resistance 
and other components of the MS, published data are 
conflicting9-14. Syndrome Z (SZ) is defined as the co-
occurrence of OSA and metabolic syndrome15. 
 In the present study we analysed the data collected 
in a community based study in South Delhi, India, to 
determine the ages at which the three conditions, MS, OSA 
or syndrome Z exist in subjects undergoing sleep studies. 
The data were stratified according to BMI <25, > 25 and 
≥ 30 kg/m2, using 2 cut off values, 25 and 30 of BMI.
Material & Methods
Study population, polysomnography studies and 
investigations for MS: The South Delhi sleep study was 
a two-stage cross-sectional study aimed at determining 
the prevalence and risk factors for OSA in middle-aged 
urban Indians. The study design and recruitment of 
subjects are detailed elsewhere16. 
 A total of 365 subjects consented and underwent 
in hospital polysomnography (PSG), detailed 
anthropometry and blood pressure recording made 
as described previously16. Polysomnography studies 
were scored manually according to standard criteria by 
trained technicians17,18 . The OSA was defined as apnoea-
hypopnoea index (AHI) > 5. Various biochemical 
investigations were carried out in these subjects as 
described previously 19.  At the end of the sleep study on 
the next morning fasting blood samples were taken from 
each subject for the following biochemical tests: blood 
sugar (glucose oxidase method) and lipid profile (total 
cholesterol, LDL, HDL cholesterol and triglycerides). 
Total cholesterol, triglycerides and HDL-cholesterol 
were measured using immunocolorimetric assay while 
LDL-cholesterol was derived indirectly using the 
Freidwald equation20.
Metabolic syndrome: The MS was defined according 
to NCEP-ATP III21 criteria. The cut-offs for defining 
abdominal obesity based on waist circumference were 
taken as > 90 cm in males and > 80 cm in females22. 
Likewise, a lower cut-off of BMI (25) was used to 
define obesity23. Subjects having 3 of 5 criteria were 
said to have MS. 
 The magnitude of the three conditions and the 
minimum and median ages of the three groups 
(MS, OSA, SZ) were compared to get an idea about 
the sequence of the three events. Box-plots were 
constructed using Stata 9.2 (Stata Corporation Inc. 
College Station, Texas, USA). Comparison of clinical 
and laboratory parameters among various group was 
done by One-way ANOVA.
Results & Comment
 The Table provides comparison of clinical and 
laboratory parameters among four groups in 351 
subjects. The MS was observed in 105 [29.9% (95 % 
CI 25.1-34.7)] of the subjects studied while the OSA 
Table. Comparison of clinical and laboratory parameters among various groups
Component Normal
(n=152)
Metabolic 
syndrome
(n=105)
Obstructive sleep 
apnoea
(n=24)
Syndrome-Z
(n=70)
P value*
Fasting blood sugar (mg/dl) 97.3 ± 32.9 110 ± 39.9 94 ± 9 108.5 ± 38.4 0.01
Serum cholesterol – total (mg/dl) 191.3 ± 41.6 212.3 ± 44.5 197.6 ± 48 214.4 ± 47.7 <0.001
Triglycerides (mg/dl) 133.4 ± 52.9 193.8 ± 69.3 141 ± 48.6 204.3 ± 78.8 <0.001
Serum HDL (mg/dl) 52 ± 9.6 45.4 ± 10.3 55 ± 16.1 40.9 ± 9.3 <0.001
Serum LDL (mg/dl) 112.6 ± 38 128.1 ± 38.8 114.3 ± 44.3 132.7 ± 39.6 <0.001
Waist circumference (cm) 90.6 ± 13.3 99 ± 10 105.4 ± 20.4 109 ± 11.2 <0.001
Systolic BP (mm Hg) 124.8 ± 11.1 137.9 ± 18.6 129.8 ± 14.3 140.1 ± 17.1 <0.001
Diastolic BP (mm Hg) 82 ± 8.9 90.8 ± 12.4 85.8 ± 6.3 91.6 ± 12.5 <0.001
Apnoea-hypoapnoea index (events/h) 0.5 ± 1.1 0.9 ± 1.3 24.8 ± 18.3 33.2 ± 26.12 <0.001
BMI (kg/m2) 24.76 ± 5.63 28.24 ± 4.27 28.58 ± 8.39 31.73 ± 5.62 <0.001
*By one-way ANOVA
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and syndrome Z were seen in 24 [6.8% (95% CI 4.2-
9.5)] and 70 [19.9% (95% CI 15.8-24.1)] individuals 
respectively. 
 The ages of the subjects in the four groups (Fig. 
a) showed that the medians age increased from 40 yr 
among normal subjects to 47 yr among the subjects 
with syndrome Z. The two groups of subjects with MS 
alone and OSA alone had similar median age of 43 yr. 
Gradual increase in the median ages of four groups 
were observed among those with BMI < 25 (kg/m2) 
(39, 44, 45 and 50 yr) in the four groups of normal, MS 
alone, OSA alone and SZ respectively) (Fig. b). The 
minimum ages also showed similar trend of the subjects 
in the 4 groups i.e. 30, 30, 36 and 47 yr respectively. 
Among persons with BMI >25, the differences in the 
median ages among the 4 groups were less distinct, 
namely 41, 43, 43 and 45 yr respectively, while the 
minimal ages were 30, 30, 32 and 32 yr respectively 
(Fig. b).
 In the morbidly obese group (BMI ≥ 30), the median 
ages of MS alone and OSA alone groups were 2 and 
3 yr lesser than that of normal persons whose median 
age was 45 yr. The minimal ages observed among the 4 
groups were 30, 30, 40 and 34 yr respectively (Fig.  c).
 The decreasing magnitude of the three conditions 
together with the increases in median and minimum ages 
observed, indicate that in the spectrum of developing 
syndrome Z, MS is the first followed by OSA. However, 
among those who are morbidly obese (according to the 
lower cut-off of BMI as recommended by WHO for the 
south Asian countries), this distinction seems to be less 
clear. This might be attributed to the presence of other 
co-morbidities such as diabetes mellitus, hypertension 
which are more frequent among excessively obese 
persons. 
 In conclusion, findings of this study provide 
an indication that in subjects with normal BMI, MS 
develops first followed by OSA. The biological 
significance of these results is not clear at present. 
It is plausible that differential activation of selective 
genes may be possible through gene environment 
interaction and appearance of these conditions. Being 
a cross-sectional in nature, this study can not answer 
a temporal relationship definitively. To have a better 
understanding about which occurs first before a person 
develops syndrome Z, a well-planned cohort study on 
presently normal individuals with regular monitoring 
including polysomnography and various metabolic 
parameters is required. This is an important issue 
Fig. a. Box plots showing ages (median and ranges) in normal 
subjects, and subjects with MS, OSA and syndrome Z. Fig. b. Box 
plots showing ages (median and ranges) in normal subjects, and 
subjects with MS, OSA and syndrome Z according to BMI <25 and 
> 25 kg/m2. Fig. c. Box plots showing ages (median and ranges) 
in normal subjects, and subjects with MS, OSA and syndrome Z 
according to BMI <30 and >30 kg/m2.
BMI, body mass index; MS, metabolic syndrome alone; OSA, 
obstructive sleep apnoea alone; S-Z, syndrome Z.
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for the future research as the prevalence of obesity 
is increasing worldwide and with this increase the 
prevalence of OSA, MS and syndrome Z will also 
increase tremendously. This will require urgent 
public health intervention strategies otherwise health 
resources of the developing and developed nations will 
be overburdened. 
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